Lung Cancer

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

Misty D. Shields, MD, PhD, discusses the implications of the ADRIATIC trial of adjuvant therapy with durvalumab vs placebo in patients with LS-SCLC.

Corey J. Langer, MD, discusses how the use of adjuvant immunotherapy has affected the resectable NSCLC treatment paradigm.

Alexander I. Spira MD, PhD, FACP, FASCO, details the next steps for amivantamab in patients with EGFR–mutated locally advanced non–small cell lung cancer.

The REZILIENT1 study of zipalertinib in pretreated patients with NSCLC harboring EGFR exon 20 insertion mutations met its primary end point of ORR.

Findings from an oncogene overlap study in NSCLC support the potential clinical impact of high-level amplification of MET, HER2, and KRAS defined by NGS.

Alexander Watson, MD, DPhil, FRCPC, explains how the relationship between driver positivity and amplification status affects same-gene alteration enrichment.

Hidehito Horinouchi, MD, PhD, discusses safety data for adjuvant alectinib vs chemotherapy in ALK-positive non–small cell lung cancer.

Alexander Watson, MD, DPhil, FRCPC, details findings showing oncogene overlap is adequately applied to NGS-based tissue sampling by decreasing frequency and increasing copy number gain.

This segment discusses the importance of biomarker testing in lung cancer, challenges in implementation such as tissue adequacy and result delays, and strategies to enhance testing in both academic and community settings through local champions and education.

This segment explores the role of biomarker testing in optimizing outcomes for non-small cell lung cancer (NSCLC), highlighting challenges in early-stage testing, the importance of multidisciplinary collaboration, and recent advances like the LAURA trial that emphasize the need for comprehensive biomarker assessment.

This video segment discusses defining resectability for Stage III lung cancer, the importance of a multidisciplinary approach to decision-making involving surgical, medical, radiation oncology, and diagnostic teams, and the role of patient engagement in tailoring treatment plans to individual priorities, risks, and physiological suitability.

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

The second-line setting for HER2-mutated NSCLC is shifting with TKIs looking to demonstrate efficacy and T-DXd under examination in the frontline now.

Sotorasib doublet gets approved for KRAS G12C–mutated CRC, acalabrutinib triplet is cleared for previously untreated MCL, and more from OncLive.

Ewa Kalinka, MD, PhD, discusses interim phase 2 data with frontline BMS-986012 plus nivolumab and chemotherapy in extensive-stage small cell lung cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Alison Schram, MD, details data from the eNRGy study that supported the FDA approval of zenocutuzumab in NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Suresh Senan, MRCP, FRCR, PhD, details how the FDA approval of durvalumab has changed care for patients with limited-stage small cell lung cancer.

Benjamin P. Levy, MD, shares insight on current challenges with TROP2-directed antibody-drug conjugates in NSCLC.

Savolitinib has received full NMPA approval for locally advanced/metastatic non–small cell lung cancer with MET exon 14 skipping alterations.

Nicolas Girard, MD, discusses differences in the mechanisms of action for HER2-directed TKIs vs antibody-drug conjugates in HER2-mutant NSCLC.

The BLA for Dato-DXd in locally advanced or metastatic EGFR-mutated NSCLC has been accepted and granted priority review by the FDA.

Sunvozertinib gets priority review in EGFR-mutated NSCLC, iparomlimab/tuvonralimab combination elicits responses in cervical cancer, and more.

Data from a phase 2 trial demonstrated that abenacianine is a safe investigational tumor-targeted fluorescent imaging agent for tumors in the lung.